Issue 4, 2025, Issue in Progress

Design, synthesis, anti-inflammatory evaluation, and molecular docking studies of novel quinazoline-4(3H)-one-2-carbothioamide derivatives

Abstract

In this paper, a series of novel quinazoline-4(3H)-one-2-carbothioamide derivatives (8a–p) were designed and synthesized via the Wilgerodt–Kindler reaction between 2-methylquinazoline-4-one 10 and amines using S8/DMSO as the oxidizing system. Their characteristics were confirmed by IR, NMR, HRMS spectra, and their melting point. These novel derivatives (8a–p) were evaluated for their anti-inflammatory activity by inhibiting NO production in lipopolysaccharide (LPS)-activated RAW 264.7 macrophage cells. Compounds 8d (IC50 = 2.99 μM), 8g (IC50 = 3.27 μM), and 8k (IC50 = 1.12 μM) exhibited potent inhibition of NO production compared to the standard drug dexamethasone (IC50 = 14.20 μM). Compound 8a (IC50 = 13.44 μM) exhibited NO inhibition comparable to dexamethasone. Structure–activity relationship (SAR) studies indicated that the presence of both the thioamide functional group (NH–C[double bond, length as m-dash]S) directly attached to the phenyl ring containing halogen substituents (4-Cl, 8d), (4-Br, 8g) and (4-CF3, 8k), is responsible for the potent anti-inflammatory activity of these novel quinazolinone derivatives. Computational modeling studies revealed that compounds 8d, 8g, and 8k are potent inhibitors of TLR4 signaling through the formation of hydrophobic interactions and are stabilized by hydrogen bonds. Replacing the thioamide (8k) with an amide (8q) resulted in an 83-fold decrease in NO inhibitory potency. This highlights the important role of H-bonding involving the thioamide group. The structural shape difference results in favorable interactions of quinazolinones containing thioamide linkers compared to amide linkers to the target receptor. Furthermore, the ADMET profiles and physicochemical properties of these three lead compounds were predicted to meet the criteria for drug-like properties. Therefore, these compounds may be potential candidates for the treatment of many inflammatory diseases associated with immune disorders.

Graphical abstract: Design, synthesis, anti-inflammatory evaluation, and molecular docking studies of novel quinazoline-4(3H)-one-2-carbothioamide derivatives

Supplementary files

Article information

Article type
Paper
Submitted
30 Dec 2024
Accepted
21 Jan 2025
First published
28 Jan 2025
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2025,15, 2850-2861

Design, synthesis, anti-inflammatory evaluation, and molecular docking studies of novel quinazoline-4(3H)-one-2-carbothioamide derivatives

L. T. H. Nguyen, D. H. Vu, M. Q. Pham, Q. A. Ngo and N. B. Vo, RSC Adv., 2025, 15, 2850 DOI: 10.1039/D4RA09094B

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements